MCAM and metastatic malignant neoplasm: Currently, a number of Wnt5a receptors were reported, including Fzd2, Fzd3, Fzd4, Fzd5, Fzd6, Fzd7, Fzd8, RYK, ROR2 and CD146.35 Results from several independent studies indicated that Fzd2 expression might drive EMT through the non‐canonical Wnt pathway in different cancer cells.28, 36, 37, 38, 39 Gujral et al28 reported that Wnt5a and its ligand Fzd2 are overexpressed in several metastatic cancer cell lines and tumours.